Alvocidib prodrugs and their use as protein kinase inhibitors
Compounds having the following structure (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 and R 3 are as defined herein, and wherein at least one of R 1 , R 2 and R 3 is not H, are provided. Pharmaceutical compositions comprising the compounds and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.
1. A compound having one of the following structures:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutically acceptable salt of a compound of claim 1 .
3. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient, and a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
4. The pharmaceutical composition of claim 3 , wherein the pharmaceutical composition is formulated for oral delivery.